Literature DB >> 18854512

When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?

Josef S Smolen, Michael E Weinblatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18854512     DOI： 10.1136/ard.2008.098111

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Authors:  Liisa M Virkki; Heikki Valleala; Yuya Takakubo; Jorma Vuotila; Heikki Relas; Riitta Komulainen; Riitta Koivuniemi; Urpo Yli-Kerttula; Markku Mali; Susanna Sihvonen; Maija-Liisa Krogerus; Eero Jukka; Satu Nyrhinen; Yrjö T Konttinen; Dan C Nordström
Journal:  Clin Rheumatol       Date:  2011-06-07       Impact factor: 2.980

Review 2.  Golimumab and malignancies: true or false association?

Authors:  Ines Zidi; Aicha Bouaziz; Wissem Mnif; Aghleb Bartegi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2010-04-07       Impact factor: 3.064

3.  [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].

Authors:  J Wollenhaupt; K Krüger
Journal:  Z Rheumatol       Date:  2010-09       Impact factor: 1.372

4.  Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis.

Authors:  Ronghan Liu; Yuehong Chen; Wenyu Fu; Shuya Wang; Yazhou Cui; Xiangli Zhao; Zi-Ning Lei; Aubryanna Hettinghouse; Jody Liu; Chao Wang; Chen Zhang; Yufei Bi; Guozhi Xiao; Zhe-Sheng Chen; Chuan-Ju Liu
Journal:  Ann Rheum Dis       Date:  2019-07-13       Impact factor: 19.103

5.  Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.

Authors:  Alejandro Balsa; Juan Víctor Tovar Beltrán; Rafael Cáliz Cáliz; Isabel Mateo Bernardo; Rosario García-Vicuña; Manuel Rodríguez-Gómez; Miguel Angel Belmonte Serrano; Carlos Marras; Eduardo Loza Cortina; Eva Pérez-Pampin; Vicente Vila
Journal:  Rheumatol Int       Date:  2015-03-13       Impact factor: 2.631

Review 6.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

7.  Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.

Authors:  Bart J F van den Bemt; Alfons A den Broeder; G J Wolbink; Yechiel A Hekster; Piet L C M van Riel; Bart Benraad; Frank H J van den Hoogen
Journal:  BMC Musculoskelet Disord       Date:  2011-01-13       Impact factor: 2.362

8.  Distinctive roles of tumor necrosis factor receptor type 1 and type 2 in a mouse disc degeneration model.

Authors:  Shanzheng Wang; Guodong Sun; Pan Fan; Lei Huang; Yaofei Chen; Changhong Chen
Journal:  J Orthop Translat       Date:  2021-12-03       Impact factor: 5.191

9.  Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.

Authors:  Gianfranco Ferraccioli; Barbara Tolusso; Francesca Bobbio-Pallavicini; Elisa Gremese; Viviana Ravagnani; Maurizio Benucci; Edoardo Podestà; Fabiola Atzeni; Alice Mannocci; Domenico Biasi; Mariangela Manfredi; Piercarlo Sarzi-Puttini; Bruno Laganà; Carlomaurizio Montecucco
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

10.  Penfluridol targets acid sphingomyelinase to inhibit TNF signaling and is therapeutic against inflammatory autoimmune diseases.

Authors:  Yue-Hong Chen; Rong-Han Liu; Ya-Zhou Cui; Aubryanna Hettinghouse; Wen-Yu Fu; Lei Zhang; Chen Zhang; Chuan-Ju Liu
Journal:  Arthritis Res Ther       Date:  2022-01-19       Impact factor: 5.606
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.